First-in-Human Single and Multiple Dose of EB8018
A Randomised, Double-Blind, Placebo-Controlled Study of a Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) of a FimH Antagonist, EB8018, in Healthy Volunteers.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nottingham
-
Ruddington, Nottingham, United Kingdom, NG11 6JS
- Quotient Clinical
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy males
- Age ≥ 18 to ≤ 55 years of age
- Body mass index of 19.0 to 30.0 kg/m2
- Normal ECG, showing no clinically relevant deviations, as judged by the investigator (QTcF ≤450 ms)
Exclusion Criteria:
- Subjects who have received any Investigational Medicinal Product in a clinical research study within the previous 3 months.
- History of any drug or alcohol abuse in the past 2 years
- Regular alcohol consumption in males >21 units per week
- Current smokers and those who have smoked within the last 12 months
- Positive drugs of abuse test result
- Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever, even inactive, is not allowed.
- Chronic infection or acute significant infection or fever within the previous 5 weeks prior to the start of IMP administration
- Malignancy or prior malignancy, with a disease-free interval of less than 5 years after diagnosis and intervention
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Single oral dose of EB8018
Single ascending doses, sequential group design
|
|
|
PLACEBO_COMPARATOR: Single oral dose of placebo
Single doses, matching placebo
|
|
|
EXPERIMENTAL: Multiple oral doses of EB8018
Multiple ascending doses, daily for 14 days
|
|
|
PLACEBO_COMPARATOR: Multiple oral doses of placebo
Multiple ascending doses, daily for 14 days
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Treatment Related Adverse Event, including Abnormal Laboratory Events to evaluate the safety and tolerability profile of single ascending and multiple ascending doses of EB8018 compared with placebo in healthy subjects
Time Frame: Between screening and 7-10 days after the last dose
|
The variables for analysis will be the difference of EB8018 compared with placebo for incidence, severity and type of adverse events, including changes in vital signs, physical examinations, laboratory safety tests and ECGs
|
Between screening and 7-10 days after the last dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The amount of EB8018 in plasma
Time Frame: Between Day 1 predose and 48 hours after the (last) dose
|
To characterize the amount of EB8018 in plasma over time - pharmacokinetics (PK) - after a single oral dose and multiple oral doses in healthy subjects
|
Between Day 1 predose and 48 hours after the (last) dose
|
|
The amount of EB8018 in urine
Time Frame: Between Day 1 predose and 48 hours after the (last) dose
|
To characterize the amount of EB8018 in urine over time - pharmacokinetics (PK) - after a single oral dose and multiple oral doses in healthy subjects
|
Between Day 1 predose and 48 hours after the (last) dose
|
|
The amount of EB8018 in stool
Time Frame: Between predose and 48 hours after the (last) dose
|
To characterize the amount of EB8018 in urine over time - pharmacokinetics (PK) - after a single oral dose and multiple oral doses in healthy subjects
|
Between predose and 48 hours after the (last) dose
|
|
Analysis of microbiome richness
Time Frame: Between predose and 48 hours after the (last) dose
|
To compare the abundance of gene richness, all phyla and certain species such as E. Coli
|
Between predose and 48 hours after the (last) dose
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- EBFIM116
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.